An observational study in Type 2 Diabetes Mellitus, sponsored by Cardenal Herrera University. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Cardenal Herrera University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 38th largest by planned enrollment of the 46 observational ones that give a count, is one of 24 that started in 2026, is one of 46 observational ones, reaches primary completion later than 11 of the 54 other live ones, and was the 408th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 49 · Phase 3 209 · Phase 4 51
First in 2000; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 484 across the 383 interventional studies, 842 across the 46 observational. Of the 346 that completed or were terminated, 197 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
304 of 429 have an industry lead sponsor. The 10 most frequent:
Cardenal Herrera University is the lead sponsor of 109 studies on the registry; 23 are open to participants now.
Cardenal Herrera University has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 2 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07269015Hospital Mutua de TerrassaCGM Accuracy in Pregnancy Study | 2026-12 |
| NCT06871059University of the Balearic IslandsEffectiveness, Implementation and Spillover Effects of a Culturally Adapted DPP in Spanish Primary Care Centers | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.
Cardiovascular disease (CVD) is the leading cause of death worldwide and accounts for approximately 45% of all deaths in Europe. Beyond mortality, CVD has a substantial impact on patients' quality of life and represents a significant economic burden on healthcare systems. T2DM is a key cardiovascular risk factor and an important determinant of serious cardiovascular complications, as it is associated with a worse prognosis after cardiac events and almost doubles the risk of all-cause mortality.
Primary prevention of CVD is a cornerstone of nursing practice, especially in the management of chronic diseases such as T2DM, where lifestyle interventions and long-term follow-up are essential. Several tools are available for the early detection of CVD, including cardiovascular risk (CVR) prediction models and imaging techniques. SCORE2 and SCORE2-Diabetes are widely used algorithms for estimating the 10-year risk of major cardiovascular events in European adults. Imaging modalities, such as carotid ultrasound, are becoming increasingly relevant, not only as diagnostic tools but also as support resources in nurse-led clinical assessment, as they provide objective and visual biomarkers of vascular health.
Carotid ultrasound allows for the assessment of established parameters related to CVR, such as CIMT, echogenicity, echovariation, and wall texture. Intima-media thickness (IMT) is a well-recognized marker of arterial injury and cardiovascular risk, especially in people with T2DM. While echogenicity and echovariation reflect tissue composition and structural heterogeneity, they may not detect early microstructural alterations. In contrast, texture features derived from gray-level co-occurrence matrix (GLCM) analyze spatial relationships between pixels, allowing the detection of subtle arterial changes associated with cardiovascular risk. Therefore, in nursing practice, layer-specific carotid texture analysis may offer a more accurate and personalized assessment of cardiovascular risk.
European population aged between 40 and 69 years without known cardiovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: SCORE2-Diabetes · Diagnostic Test: Ultrasound Assessment
Diagnostic Test: SCORE2 · Diagnostic Test: Ultrasound Assessment
Will classify individuals into four cardiovascular risk categories: * For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%
Will also classify individuals into four risk categories: low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%).
Three bilateral longitudinal scans of the common carotid artery will be obtained for carotid intima-media thickness (CIMT) measurement and stratification of carotid wall layers for subsequent texture analysis. Additionally, a bilateral video recording of the same imaging plane containing a minimum of five cardiac cycles will be acquired. One end-diastolic frame per video-corresponding to the relaxed arterial wall-will be selected to standardize image acquisition and CIMT measurement.
SCORE2
* For participants aged 50-69 years: * Low-to-moderate risk: \<5% * High risk: ≥5% to \<10% * Very high risk: ≥10% * For participants aged 40-49 years: * Low-to-moderate risk: \<2.5% * High risk: ≥2.5% to \<7.5% * Very high risk: ≥7.5%
Time frame: baseline
SCORE2 - Diabetes
Low (\<5%), moderate (5-10%), high (10-20%), and very high (\>20%)
Time frame: baseline
Energy or angular second moment (ASM)
This measures the uniformity or regularity in the distribution of image values. Higher values indicate greater uniformity in the image
Time frame: baseline
Homogeneity or inverse difference moment (IDM)
This reflects the homogeneity of image composition, associated with pixel pairs. Homogeneous images with minimal variations produce high IDM valueS
Time frame: baseline
Contrast (CON)
Represents the degree of local variations in grey levels within the image. The greater the variation, the greater the contrast
Time frame: baseline
Textural correlation (TCOR)
Expresses linear dependencies between grey levels in the image. Regions with similar grey levels tend to exhibit higher values
Time frame: baseline
Entropy (ENT)
This indicates the level of disorder within the image. Homogeneous images result in lower entropy values
Time frame: baseline
Carotid intima-media thickness (CIMT)
(mm)
Time frame: baseline
Echointensity
The mean pixel intensity within an ultrasound region of interest (related to tissue brightness/echo)
Time frame: baseline
Echovariation
The variability or dispersion of pixel intensity within the ultrasound region of interest, corresponding to a measure of tissue heterogeneity
Time frame: baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data associated with this paper will be available in the Zenodo repository
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Ran from Jan 2026 to primary completion in Jan 2026, 0 months.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.